| Epidemiology and costs of chronic obstructive pulmonary disease KR Chapman, DM Mannino, JB Soriano, PA Vermeire, AS Buist, MJ Thun, ... European Respiratory Journal 27 (1), 188-207, 2006 | 1211 | 2006 |
| Indacaterol–glycopyrronium versus salmeterol–fluticasone for COPD JA Wedzicha, D Banerji, KR Chapman, J Vestbo, N Roche, RT Ayers, ... New England Journal of Medicine 374 (23), 2222-2234, 2016 | 1087 | 2016 |
| Tiotropium in combination with placebo, salmeterol, or fluticasone–salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial SD Aaron, KL Vandemheen, D Fergusson, F Maltais, J Bourbeau, ... Annals of internal medicine 146 (8), 545-555, 2007 | 1003 | 2007 |
| Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study RA Evans, HJC McAuley, EM Harrison, A Shikotra, A Singapuri, M Sereno, ... The Lancet Respiratory Medicine 9 (11), 1275-1287, 2021 | 584 | 2021 |
| Gender bias in the diagnosis of COPD KR Chapman, DP Tashkin, DJ Pye Chest 119 (6), 1691-1695, 2001 | 565 | 2001 |
| Marked flow-dependence of exhaled nitric oxide using a new technique to exclude nasal nitric oxide. PE Silkoff, PA McClean, AS Slutsky, HG Furlott, E Hoffstein, S Wakita, ... American journal of respiratory and critical care medicine 155 (1), 260-267, 1997 | 562 | 1997 |
| Intravenous augmentation treatment and lung density in severe α1 antitrypsin deficiency (RAPID): a randomised, double-blind, placebo-controlled trial KR Chapman, JGW Burdon, E Piitulainen, RA Sandhaus, N Seersholm, ... The Lancet 386 (9991), 360-368, 2015 | 540 | 2015 |
| Minimal clinically important differences in pharmacological trials PW Jones, KM Beeh, KR Chapman, M Decramer, DA Mahler, ... American journal of respiratory and critical care medicine 189 (3), 250-255, 2014 | 495 | 2014 |
| Suboptimal asthma control: prevalence, detection and consequences in general practice KR Chapman, LP Boulet, RM Rea, E Franssen European Respiratory Journal 31 (2), 320-325, 2008 | 494 | 2008 |
| Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials NA Hanania, P Korenblat, KR Chapman, ED Bateman, P Kopecky, ... The Lancet Respiratory Medicine 4 (10), 781-796, 2016 | 491 | 2016 |
| Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response. LP Boulet, KR Chapman, J Cote, S Kalra, R Bhagat, VA Swystun, ... American journal of respiratory and critical care medicine 155 (6), 1835-1840, 1997 | 490 | 1997 |
| Medical personnel's knowledge of and ability to use inhaling devices: metered-dose inhalers, spacing chambers, and breath-actuated dry powder inhalers NA Hanania, R Wittman, S Kesten, KR Chapman Chest 105 (1), 111-116, 1994 | 383 | 1994 |
| Nebulized anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room AS Rebuck, KR Chapman, R Abboud, PD Pare, H Kreisman, N Wolkove, ... The American journal of medicine 82 (1), 59-64, 1987 | 365 | 1987 |
| Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study RA Evans, OC Leavy, M Richardson, O Elneima, HJC McAuley, ... The Lancet Respiratory Medicine 10 (8), 761-775, 2022 | 358 | 2022 |
| Adverse effects of inhaled corticosteroids NA Hanania, KR Chapman, S Kesten The American journal of medicine 98 (2), 196-208, 1995 | 349 | 1995 |
| Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study ML Decramer, KR Chapman, R Dahl, P Frith, G Devouassoux, C Fritscher, ... The lancet Respiratory medicine 1 (7), 524-533, 2013 | 337 | 2013 |
| A cohort study of traffic-related air pollution and mortality in Toronto, Ontario, Canada M Jerrett, MM Finkelstein, JR Brook, MA Arain, P Kanaroglou, DM Stieb, ... Environmental health perspectives 117 (5), 772-777, 2009 | 298 | 2009 |
| Asthma control in Canada remains suboptimal: the Reality of Asthma Control (TRAC) study JM FitzGerald, LP Boulet, RA McIvor, S Zimmerman, KR Chapman Canadian respiratory journal 13 (5), 253-259, 2006 | 295 | 2006 |
| Characteristics of COPD in never-smokers and ever-smokers in the general population: results from the CanCOLD study WC Tan, DD Sin, J Bourbeau, P Hernandez, KR Chapman, R Cowie, ... Thorax 70 (9), 822-829, 2015 | 275 | 2015 |
| Adult asthma consensus guidelines update 2003 C Lemière, T Bai, M Balter, C Bayliff, A Becker, LP Boulet, D Bowie, ... Canadian respiratory journal 11, 9A-18A, 2004 | 267 | 2004 |
Shawn AaronOttawa Hospital Research Institute, University of OttawaVerified email at ohri.ca